• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Cytosorbents Corporation

    8/16/24 5:28:33 PM ET
    $CTSO
    Medical/Dental Instruments
    Health Care
    Get the next $CTSO alert in real time by email
    S-8 1 tm2421901d2_s8.htm FORM S-8

     

    As filed with the Securities and Exchange Commission on August 16, 2024

    Registration No. 333-

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

     

    FORM S-8

    REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933

     

    CYTOSORBENTS CORPORATION

    (Exact name of Registrant as specified in its charter)

     

     

     

    Delaware
    (State or other jurisdiction
    of incorporation or organization)  
    98-0373793
    (I.R.S. Employer
    Identification No.)  
    305 College Road East
    Princeton, New Jersey
    (Address of principal executive offices)
    08540
    (Zip Code)

     

     

     

    AMENDED AND RESTATED CYTOSORBENTS CORPORATION 2014 LONG-TERM INCENTIVE PLAN

    (Full title of the plan)

     

     

     

    Phillip Chan, MD
    Chief Executive Officer
    CytoSorbents Corporation
    305 College Road East
    Princeton, New Jersey
    08540
    (732) 329-8885
    David C. Schwartz, Esq.
    Morgan, Lewis & Bockius LLP
    502 Carnegie Center
    Princeton, New Jersey 08540
    (609) 919-6600
    (Name, address, telephone number,
    including area code, of agent for service)
    (With copies to)

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer ¨     Accelerated filer ¨
    Non-accelerated filer x   Smaller reporting company x
        Emerging growth company ¨

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ¨

     

     

     

     

     

     

    EXPLANATORY NOTE

     

    The Registrant is filing this Registration Statement on Form S-8 (this “Registration Statement”) for the purpose of registering 8,145,000 shares of the Registrant’s common stock, par value $0.001 per share (the “Common Stock”), which may be issued by the Registrant as more particularly described below.

     

    Plan Shares

     

    The Board of Directors of the Registrant approved an amendment (the “Amendment”) to the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan, as amended and restated effective April 12, 2019 (the “Plan”). The Amendment was subsequently approved by the Registrant’s stockholders at the Registrant’s 2024 Annual Meeting of Stockholders held on June 6, 2024. The Amendment increased the number of shares of Common Stock to be reserved and authorized for issuance under the Plan by 7,500,000 shares to 20,900,000 shares of Common Stock.

     

    Pursuant to General Instruction E to Form S-8, the contents of the Registration Statements filed by the Registrant with the Securities and Exchange Commission (the “Commission”) (File Nos. 333-203244, 333-220630, and 333-233459), with respect to securities offered pursuant to the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan are hereby incorporated by reference to the extent not otherwise amended or superseded by the contents hereof.

     

    Inducement Awards

     

    On August 14, 2024, the Registrant entered into that certain Employment Agreement by and between the Registrant and the Chief Financial Officer of the Registrant, Peter J. Mariani (the “Mariani Employment Agreement”), pursuant to which the Registrant issued to Mr. Mariani (i) 295,000 shares of Common Stock of the Registrant, which may be issued pursuant to certain inducement nonstatutory stock option awards made to Mr. Mariani in accordance with the provisions set forth in the Mariani Employment Agreement and the inducement grant exception under NASDAQ Listing Rule 5635(c)(4) and (ii) 350,000 shares of Common Stock of the Registrant, which may be issued pursuant to the inducement restricted stock unit award made to Mr. Mariani in accordance with the provisions set forth in the Mariani Employment Agreement and the inducement grant exception under NASDAQ Listing Rule 5635(c)(4).

     

     

     

     

    PART II

     

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT  

     

    Item 3. Incorporation of Documents by Reference

     

    The following documents previously filed by the Registrant with the Commission are hereby incorporated by reference in this Registration Statement:

     

    (1)The Registrant’s Annual Report on Form 10-K for the year ended December 31, 2023, filed with the Commission on March 15, 2024;

     

    (2)The Registrant’s Definitive Proxy Statement, filed with the Commission on April 19, 2024 (but only with respect to information required by Part III of its Annual Report on Form 10-K for the year ended December 31, 2023, which information updated and superseded information included in Part III of its Annual Report on Form 10-K for the year ended December 31, 2023);

     

    (3)The Registrant’s Quarterly Reports on Form 10-Q for the fiscal quarter ended March 31, 2024, filed with the Commission on May 9, 2024 and for the fiscal quarter ended on June 30, 2024, filed with the Commission on August 13, 2024;

     

    (4)The Registrant’s Current Reports on Form 8-K filed with the Commission on January 17, 2024, March 15, 2024, April 3, 2024, May 6, 2024, May 9, 2024, May 22, 2024, June 10, 2024, July 5, 2024, August 1, 2024, August 14, 2024, and August 16, 2024 (provided that any portions of such reports that are deemed furnished and not filed pursuant to instructions to Form 8-K shall not be incorporated by reference into this Registration Statement); and

     

    (5) The description of the Registrant’s Common Stock contained in the Registrant’s Registration Statement on Form 8-A filed with the Commission on December 17, 2014, pursuant to Rule 12g-3 promulgated under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), as updated by Exhibit 4.1 to the Annual Report on Form 10-K for the fiscal year ended December 31, 2023, filed on March 15, 2024, including any amendment or report filed for the purpose of updating such description.

     

    To the extent that any information contained in any Current Report on Form 8-K, or any exhibit thereto, was furnished to, rather than filed with, the Commission, such information or exhibit is specifically not incorporated by reference.

     

    In addition, all documents that the Registrant files pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act subsequent to the effective date of this Registration Statement (except for any portions of the Registrant’s Current Reports on Form 8-K furnished pursuant to Item 2.02 or Item 7.01 thereof and any corresponding exhibits thereto not filed with the Commission), but prior to the filing of a post-effective amendment to this Registration Statement indicating that all securities offered hereby have been sold or which deregisters all securities then remaining unsold shall be deemed to be incorporated by reference in this Registration Statement and to be a part hereof from the date of filing such documents.

     

    For purposes of this Registration Statement, any document or statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded to the extent that a statement contained herein or in any other subsequently filed document which also is or is deemed to be incorporated by reference herein modifies or supersedes such document or statement in such document. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

     

     

     

     

    EXHIBIT INDEX

     

    Exhibit
    number
      Description
         
    5.1   Opinion of Morgan, Lewis & Bockius LLP, counsel for the Registrant, (filed herewith).
         
    10.1   Employment Agreement by and between the Registrant and Peter Mariani (incorporated by reference from Exhibit 10.1 to the Registrant’s Current Report on Form 8-K filed on August 16, 2024)
         
    23.1   Consent of Morgan, Lewis & Bockius LLP (included in Exhibit 5.1).
         
    23.2   Consent of WithumSmith+Brown, PC, the Registrant’s Independent Registered Public Accounting Firm (filed herewith).
         
    24.1   Power of Attorney (included on signature page).
         
    99.1   Restricted Stock Unit Award Agreement (Inducement Award), dated as of August 14, 2024, by and between the Registrant and Peter Mariani (incorporated by reference from Exhibit 10.1 to the Registrant’s Current Report on Form 8-K filed on August 16, 2024)
         
    99.2   Nonstatutory Option Award Agreement (Inducement Award), dated as of August 14, 2024, by and between the Registrant and Peter Mariani (incorporated by reference from Exhibit 10.1 to the Registrant’s Current Report on Form 8-K filed on August 16, 2024)
         
    99.3   Nonstatutory Option Award Agreement (Inducement Award), dated as of August 14, 2024, by and between the Registrant and Peter Mariani (incorporated by reference from Exhibit 10.1 to the Registrant’s Current Report on Form 8-K filed on August 16, 2024)
         
    107   Filing Fee Exhibit

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in Princeton, New Jersey, August 16, 2024.

     

      CYTOSORBENTS CORPORATION
       
      By: /s/ Dr. Phillip P. Chan
      Name:   Dr. Phillip P. Chan
      Title: Chief Executive Officer

     

     

     

     

    POWER OF ATTORNEY

     

    We, the undersigned officers and directors of CytoSorbents Corporation, hereby severally constitute and appoint Phillip P. Chan and Peter J. Mariani, our true and lawful attorneys, with full power to each of them singly, to sign for us and in our names in the capacities indicated below, the Registration Statement on Form S-8 filed herewith and any and all subsequent amendments to said Registration Statement, and generally to do all such things in our names and on our behalf in our capacities as officers and directors to enable CytoSorbents Corporation to comply with the provisions of the Securities Act of 1933 as amended, and all requirements of the Securities and Exchange Commission, hereby ratifying and confirming our signatures as they may be signed by our said attorneys, or any of them, to said Registration Statement and any and all amendments thereto.

     

    Pursuant to the requirements of the Securities Act of 1933, as amended this Registration Statement has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

     

     

    Signature   Title   Date
    /s/ Michael G. Bator   Chairman of the Board of Directors   August 16, 2024
    Michael G. Bator        
             
    /s/ Dr. Phillip P. Chan   Chief Executive Officer (Principal Executive Officer) and Director   August 16, 2024
    Dr. Philip P. Chan        
             
    /s/ Peter J. Mariani   Chief Financial Officer (Principal Financial and Accounting Officer)   August 16, 2024
    Peter J. Mariani        
             
    /s/ Alan D. Sobel   Director   August 16, 2024
    Alan D. Sobel        
             
    /s/ Edward R. Jones   Director   August 16, 2024
    Edward R. Jones        
             
    /s/ Jiny Kim   Director   August 16, 2024
    Jiny Kim        

     

     

     

    Get the next $CTSO alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CTSO

    DatePrice TargetRatingAnalyst
    9/7/2023$4.00Buy
    B. Riley Securities
    10/14/2021$10.00Buy
    B. Riley Securities
    More analyst ratings

    $CTSO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    CytoSorbents Reports Preliminary Unaudited Fourth Quarter and Full-Year 2025 Results and Business Update

    Fourth quarter and Full-Year 2025 revenue are expected to be approximately $9.2 million and $37.0 million, respectively, with expected Q4 gross margins in the range of 73% to 75% DrugSorb®-ATR De Novo Pre-Submission Meeting scheduled with the FDA this month, with anticipated De Novo Application filing this quarter and regulatory decision in mid-2026 Results of the pivotal STAR-T study for DrugSorb®-ATR have recently been accepted for publication in a top cardiac surgery journal Management will host in-person investor meetings in San Francisco during J.P. Morgan Healthcare Conference week PRINCETON, N.J., Jan. 12, 2026 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ:CTSO), a leader in the tr

    1/12/26 7:00:00 AM ET
    $CTSO
    Medical/Dental Instruments
    Health Care

    CytoSorbents to Participate in a Virtual Fireside Chat with D. Boral Capital on Monday, December 15, 2025

    PRINCETON, N.J., Dec. 10, 2025 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ:CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, today announced that Dr. Phillip Chan, CEO, and Peter J. Mariani, CFO, will join Jason Kolbert, Head of Healthcare Research at D. Boral Capital, for a virtual fireside chat. Building on the Company's recent third quarter earnings call, highlighting $37.0 million in trailing 12-month high-margin sales, a strengthened balance sheet, and ongoing regulatory progress for DrugSorb™-ATR with the U.S. Food and Drug Administration (FDA) and a key regulatory decision expected in mid-2026,

    12/10/25 7:00:00 AM ET
    $CTSO
    Medical/Dental Instruments
    Health Care

    Updated: CytoSorbents to Present at the Jefferies Global Healthcare Conference in London

    PRINCETON, N.J., Nov. 17, 2025 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ:CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, today announced that management will present and participate in one-on-one meetings with investors at the Jefferies Global Healthcare Conference, being held on November 17-20, 2025 in London, United Kingdom. CTSO) is a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification. CytoSorbents' flagship product, CytoSorb(R), is approved in the Euro

    11/17/25 5:42:00 PM ET
    $CTSO
    Medical/Dental Instruments
    Health Care

    $CTSO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Chan Phillip P. was granted 100,000 shares, increasing direct ownership by 7% to 1,482,963 units (SEC Form 4)

    4 - Cytosorbents Corp (0001175151) (Issuer)

    11/20/25 9:09:45 PM ET
    $CTSO
    Medical/Dental Instruments
    Health Care

    Chief Executive Officer Chan Phillip P. was granted 105,600 shares, increasing direct ownership by 8% to 1,382,963 units (SEC Form 4)

    4 - Cytosorbents Corp (0001175151) (Issuer)

    8/8/25 7:40:26 PM ET
    $CTSO
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Director Jones Edward Raymond

    4 - Cytosorbents Corp (0001175151) (Issuer)

    8/8/25 7:39:21 PM ET
    $CTSO
    Medical/Dental Instruments
    Health Care

    $CTSO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    B. Riley Securities initiated coverage on CytoSorbents with a new price target

    B. Riley Securities initiated coverage of CytoSorbents with a rating of Buy and set a new price target of $4.00

    9/7/23 8:13:32 AM ET
    $CTSO
    Medical/Dental Instruments
    Health Care

    B. Riley Securities resumed coverage on CytoSorbents with a new price target

    B. Riley Securities resumed coverage of CytoSorbents with a rating of Buy and set a new price target of $10.00

    10/14/21 7:58:45 AM ET
    $CTSO
    Medical/Dental Instruments
    Health Care

    $CTSO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Mariani Peter J bought $19,294 worth of shares (20,000 units at $0.96), increasing direct ownership by 5% to 401,363 units (SEC Form 4)

    4 - Cytosorbents Corp (0001175151) (Issuer)

    12/16/24 7:00:11 AM ET
    $CTSO
    Medical/Dental Instruments
    Health Care

    Chief Financial Officer Mariani Peter J bought $27,975 worth of shares (31,363 units at $0.89), increasing direct ownership by 9% to 381,363 units (SEC Form 4)

    4 - Cytosorbents Corp (0001175151) (Issuer)

    12/13/24 8:00:13 AM ET
    $CTSO
    Medical/Dental Instruments
    Health Care

    Sobel Alan D. bought $30,001 worth of shares (22,557 units at $1.33), increasing direct ownership by 28% to 101,857 units (SEC Form 4)

    4 - Cytosorbents Corp (0001175151) (Issuer)

    12/15/23 4:35:14 PM ET
    $CTSO
    Medical/Dental Instruments
    Health Care

    $CTSO
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Cytosorbents Corporation

    SCHEDULE 13G/A - Cytosorbents Corp (0001175151) (Subject)

    2/13/26 5:56:29 PM ET
    $CTSO
    Medical/Dental Instruments
    Health Care

    Cytosorbents Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Cytosorbents Corp (0001175151) (Filer)

    11/13/25 4:34:39 PM ET
    $CTSO
    Medical/Dental Instruments
    Health Care

    SEC Form 10-Q filed by Cytosorbents Corporation

    10-Q - Cytosorbents Corp (0001175151) (Filer)

    11/13/25 4:32:19 PM ET
    $CTSO
    Medical/Dental Instruments
    Health Care

    $CTSO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Cytosorbents Corporation

    SC 13G/A - Cytosorbents Corp (0001175151) (Subject)

    11/14/24 4:48:32 PM ET
    $CTSO
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G filed by Cytosorbents Corporation

    SC 13G - Cytosorbents Corp (0001175151) (Subject)

    2/14/24 4:42:32 PM ET
    $CTSO
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G filed by Cytosorbents Corporation

    SC 13G - Cytosorbents Corp (0001175151) (Subject)

    2/14/24 9:00:04 AM ET
    $CTSO
    Medical/Dental Instruments
    Health Care

    $CTSO
    Leadership Updates

    Live Leadership Updates

    View All

    CytoSorbents Appoints Melanie Grossman, CPA as Vice President and Corporate Controller

    Ms. Grossman brings 25 years of accomplished finance and accounting experience in global, publicly-traded companies Company announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) PRINCETON, N.J., April 17, 2025 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ:CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, today announced the appointment of Melanie Grossman, CPA as Vice President and Corporate Controller.  Ms. Grossman joins CytoSorbents with over 25 years of accomplished finance and accounting experience in global, publicly-traded companies. 

    4/17/25 7:00:00 AM ET
    $CTSO
    Medical/Dental Instruments
    Health Care

    CytoSorbents Appoints Thomas Shannon as Vice President of Marketing for North America

    PRINCETON, N.J., April 14, 2025 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ:CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, today announced the appointment of Thomas Shannon as Vice President of Marketing for North America. With anticipated marketing approval, Mr. Shannon will lead the marketing strategy and execution for DrugSorb™-ATR in the U.S. and Canada. CTSO) is a leader in the treatment of life-threatening conditions using blood purification. CytoSorbents' flagship product, CytoSorb®, is approved in the European Union and di

    4/14/25 7:00:00 AM ET
    $CTSO
    Medical/Dental Instruments
    Health Care

    CytoSorbents And Converge Biotech Announce Strategic Partnership to Expand Sepsis and Critical Care Treatment with CytoSorb in India

    PRINCETON, N.J. and HYDERABAD, India, Nov. 11, 2024 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ:CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit (ICU) and during cardiac surgery through blood purification, and Converge Biotech, a prominent healthcare company with a strong critical care and infectious disease focus in India, are pleased to announce a new strategic collaboration where the two companies seek to expand their combined market reach in the sepsis and critical care markets in India with a broad synergistic product portfolio. CytoSorbents is renowned for its flagship product, CytoSorb®, a blood purification technology that red

    11/11/24 7:30:00 AM ET
    $CTSO
    Medical/Dental Instruments
    Health Care

    $CTSO
    Financials

    Live finance-specific insights

    View All

    CytoSorbents Reports Third Quarter 2025 Financial Results and Provides Business Update

    Third quarter 2025 revenue of $9.5 million, up 10% year-over-yearAmended credit agreement with Avenue Capital Group which strengthens our balance sheet with an additional $2.5 million of cash, and extends the interest only-period through December 31, 2026, with an additional $2.5 million available and an additional extension of the interest-only period to June 30, 2027 with DrugSorb-ATR FDA marketing approvalImplemented Workforce and Cost Reduction Program to accelerate path to cash-flow breakeven to Q1 2026Submitted DrugSorb™-ATR De Novo pre-submission package to FDA, with meeting expected in Q4 2025 or early Q1 2026, followed by planned submission of new De Novo application in Q1 2026, and

    11/13/25 4:05:00 PM ET
    $CTSO
    Medical/Dental Instruments
    Health Care

    CytoSorbents to Report Third Quarter 2025 Financial Results and Recent Business Highlights

    PRINCETON, N.J., Oct. 30, 2025 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ:CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, will report third quarter 2025 financial results and recent business highlights after the market close on Thursday, November 13, 2025. CTSO) is a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification. CytoSorbents' flagship product, CytoSorb(R), is approved in the European Union and distributed in over 70 countries worldwide. CytoSorbents i

    10/30/25 7:00:00 AM ET
    $CTSO
    Medical/Dental Instruments
    Health Care

    CytoSorbents Reports Second Quarter 2025 Financial Results and Provides Business Update

    PRINCETON, N.J., Aug. 7, 2025 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ:CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, today reported financial results for the second quarter ended June 30, 2025, and recent business highlights.  CTSO) is a leader in the treatment of life-threatening conditions using blood purification. CytoSorbents' flagship product, CytoSorb®, is approved in the European Union and distributed in over 70 countries worldwide. CytoSorbents is conducting trials to support FDA marketing approval of DrugSorb™-ATR for

    8/7/25 4:00:00 PM ET
    $CTSO
    Medical/Dental Instruments
    Health Care